Effects of alpha1-adrenergic receptor blockade by doxazosin on renin-angiotensin system-regulating aminopeptidase and vasopressin-degrading activities in male and female rat thalamus.
The thalamus has connections with central autonomic centers involved in cardiovascular control and is enervated by noradrenergic fibers. The excitability of thalamic neurons is due to a reduction of ionic currents mediated by alpha(1)-adrenoceptors. The brain renin- angiotensin system (RAS) and the peptide hormone arginine-vasopressin (AVP) are also involved in the central control of blood pressure, and fluid and electrolyte homeostasis. It has been extensively reported that aminopeptidase A (APA), aminopeptidase B (APB), aminopeptidase N (APN), and vasopressin-degrading cystyl aminopeptidase activity (AVP-DA) play an important role in the regulation of the activity of angiotensins and AVP. We have analyzed the effect of alpha(1)-adrenoceptor blockade by doxazosin on RAS-regulating aminopeptidase activities and AVP-DA in soluble and membrane-bound fractions of male and female rat thalamus. Our results show that alpha(1)-adrenoceptors blockade by doxazosin does not modify the RAS through its degrading peptidases at thalamic level either in male or female rats. However, alpha(1)-adrenoceptors blockade shows gender differences in AVP-DA, increasing in males but not in females, supporting an increased capacity of males against females to degrade AVP and, therefore, to regulate cardiovascular homeostasis, under this pharmacological manipulation.
de la Chica-Rodríguez
S
S
Experimental and Clinical Physiopathology Research Group, Department of Health Sciences, Faculty of Experimental and Health Sciences, University of Jaén, Jaén, Spain.
Cortés-Denia
P
P
Ramírez-Expósito
M J
MJ
Martínez-Martos
J M
JM
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000626:Aminopeptidases / Q000187:drug effects / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism*; D018826:CD13 Antigens / Q000187:drug effects / Q000378:metabolism; D002320:Cardiovascular Physiological Phenomena; D010122:Cystinyl Aminopeptidase / Q000187:drug effects / Q000378:metabolism; D017292:Doxazosin / Q000494:pharmacology*; D005260:Female; D043384:Glutamyl Aminopeptidase / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000187:drug effects; D012737:Sex Factors; D018709:Statistics, Nonparametric; D013788:Thalamus / Q000187:drug effects / Q000201:enzymology*
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D018340:Receptors, Adrenergic, alpha-1; D001127:Arginine Vasopressin; D000626:Aminopeptidases; D018826:CD13 Antigens; D010122:Cystinyl Aminopeptidase; C019721:aminopeptidase B; D043384:Glutamyl Aminopeptidase; D017292:Doxazosin